SEC Filings

Form 10-Q
PROTEON THERAPEUTICS INC filed this Form 10-Q on 08/07/2017
Document Outline
Entire Document (1755.8 KB)
Subdocument 1 - 10-Q - FORM 10-Q
Page 1 - UNITED STATES
Page 2 - N/A
Page 3 - N/A
Page 4 - CAUTIONARY NOTE FORWARD-LOOKING STATEMENTS
Page 5 - N/A
Page 6 - PART I FINANCIAL INFORMATION
Page 7 - Proteon Therapeutics, Inc.
Page 8 - Proteon Therapeutics, Inc.
Page 9 - Proteon Therapeutics, Inc.
Page 10 - Fair Value of Financial Instruments
Page 11 - Derivative Financial Instruments
Page 12 - Restricted cash related to facilities leases
Page 13 - Stock Options
Page 14 - Improvements to Employee Share-Based Payment Accounting
Page 15 - Item 2. Management s Discussion and Analysis of Financial Condition and Results of Operations
Page 16 - Recent Developments
Page 17 - General and Administrative Expenses
Page 18 - Investment Income
Page 19 - Results of Operations
Page 20 - Comparison of the Six Months Ended June 30, 2017 and 2016
Page 21 - Liquidity and Capital Resources
Page 22 - Cash Flows
Page 23 - JOBS Act
Page 24 - Changes in Internal Control Over Financial Reporting
Page 25 - Item 1A. Risk Factors
Page 26 - We will require substantial additional financing to achieve our goals, and a failure to obtain this
Page 27 - We have never generated any revenue from product sales and may never be profitable.
Page 28 - Risks Related to Clinical Development, Regulatory Review and Approval of Our Product
Page 29 - Clinical development is a lengthy and expensive process with an uncertain outcome due to many factor
Page 30 - If clinical trials of vonapanitase or any additional product candidates fail to demonstrate safety a
Page 31 - N/A
Page 32 - We may face difficulty in enrolling patients for clinical trials.
Page 33 - N/A
Page 34 - Any product for which we obtain FDA approval will be subject to extensive ongoing regulatory require
Page 35 - Vonapanitase may cause undesirable side effects or have other properties that could delay or prevent
Page 36 - A breakthrough therapy, fast track product, priority review, or other designation by the FDA for our
Page 37 - Even if we obtain and maintain approval for vonapanitase or additional product candidates from the F
Page 38 - If we are found in violation of federal or state fraud and abuse laws or other healthcare laws and r
Page 39 - We may not be able to comply with requirements of foreign jurisdictions in conducting trials outside
Page 40 - Even if vonapanitase or any additional product candidates receive regulatory approval, they may fail
Page 41 - Vonapanitase or any additional product candidates, if approved, may face significant competition and
Page 42 - If the government or other third-party payors fail to provide adequate and timely coverage and payme
Page 43 - Risks Related to Dependence on Third Parties
Page 44 - Currency fluctuations in the Swiss Franc and changes in exchange rates could adversely affect our bu
Page 45 - We rely on third parties to conduct, supervise and monitor our clinical trials. If these third parti
Page 46 - We may seek to form partnerships in the future with respect to vonapanitase or any additional produc
Page 47 - Risks Related to Our Intellectual Property
Page 48 - Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure
Page 49 - Third-party claims of intellectual property infringement or misappropriation may prevent or delay ou
Page 50 - If we are unable to adequately protect our proprietary technology, or obtain and maintain issued pat
Page 51 - N/A
Page 52 - We may be subject to claims challenging the inventorship or ownership of our patents and other intel
Page 53 - We will not seek to protect our intellectual property rights in all jurisdictions throughout the wor
Page 54 - If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legi
Page 55 - Mayo Collaborative Services v. Prometheus Laboratories, Inc.
Page 56 - Risks Related to Our Business and Industry
Page 57 - Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Page 58 - If we engage in acquisitions in the future, we will incur a variety of costs and we may never realiz
Page 59 - We currently have our API produced for us by a contract manufacturer exclusively in one manufacturin
Page 60 - We have broad discretion in our use of our cash and cash equivalents and may not use them effectivel
Page 61 - Governments outside the United States tend to impose strict price controls, which may adversely affe
Page 62 - The market price for our Common Stock may be volatile, which could contribute to the loss of your in
Page 63 - Actual or potential sales of our Common Stock by our employees, including our executive officers, pu
Page 64 - Our issuance of Common Stock under our At-The-Market offering program may be dilutive, and there may
Page 65 - If securities analysts do not publish research or reports about our business or if they downgrade ou
Page 66 - We will incur significant increased costs as a result of operating as a public company, and our mana
Page 67 - We could be subject to securities class action litigation.
Page 68 - Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Page 69 - Item 6. Exhibits
Page 70 - SIGNATURES
Page 71 - EXHIBIT INDEX
Subdocument 2 - EX-31.1 - EXHIBIT 31.1
Page 1 - Exhibit 31.1
Subdocument 3 - EX-31.2 - EXHIBIT 31.2
Page 1 - Exhibit 31.2
Subdocument 4 - EX-32.1 - EXHIBIT 32.1
Page 1 - Exhibit 32.1
XBRL Item - EX-101.INS - XBRL INSTANCE FILE (What's this?)
XBRL Item - EX-101.SCH - XBRL SCHEMA FILE (What's this?)
XBRL Item - EX-101.CAL - XBRL CALCULATION FILE (What's this?)
XBRL Item - EX-101.DEF - XBRL DEFINITION FILE (What's this?)
XBRL Item - EX-101.LAB - XBRL LABEL FILE (What's this?)
XBRL Item - EX-101.PRE - XBRL PRESENTATION FILE (What's this?)
XBRL Viewer